ATHX vs. APVO, AMPE, OBSV, CALA, ALLR, SXTC, ADTX, BLPH, EVLO, and EVFM
Should you be buying Athersys stock or one of its competitors? The main competitors of Athersys include Aptevo Therapeutics (APVO), Ampio Pharmaceuticals (AMPE), ObsEva (OBSV), Calithera Biosciences (CALA), Allarity Therapeutics (ALLR), China SXT Pharmaceuticals (SXTC), Aditxt (ADTX), Bellerophon Therapeutics (BLPH), Evelo Biosciences (EVLO), and Evofem Biosciences (EVFM). These companies are all part of the "pharmaceutical preparations" industry.
Aptevo Therapeutics (NASDAQ:APVO) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.
Aptevo Therapeutics has higher revenue and earnings than Athersys.
In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 1 articles in the media. Athersys' average media sentiment score of 0.47 beat Aptevo Therapeutics' score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media.
Aptevo Therapeutics has a beta of 4.89, indicating that its stock price is 389% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, indicating that its stock price is 190% less volatile than the S&P 500.
Aptevo Therapeutics' return on equity of 0.00% beat Athersys' return on equity.
8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 19.4% of Athersys shares are held by institutional investors. 1.9% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 0.0% of Athersys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Athersys received 167 more outperform votes than Aptevo Therapeutics when rated by MarketBeat users. Likewise, 60.63% of users gave Athersys an outperform vote while only 52.66% of users gave Aptevo Therapeutics an outperform vote.
Summary
Aptevo Therapeutics beats Athersys on 7 of the 12 factors compared between the two stocks.
Get Athersys News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Athersys Competitors List
Related Companies and Tools
